Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.

The Journal of infectious diseases - 15 Jan 2016

Zhou Nannan, Hernandez Dennis, Ueland Joseph, Yang Xiaoyan, Yu Fei, Sims Karen, Yin Philip D, McPhee Fiona

Abstract excerpt

BACKGROUND: Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1-4. To support daclatasvir use in HCV genotype 4 infection, we examined a diverse genotype 4-infected population for HCV genotype 4 subtype prevalence, NS5A polymorphisms at residues associated with daclatasvir resistance (positions 28, 30, 31, or 93), and their effects on daclatasvir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Gene Expression Regulation, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Global Health

Share to Hepatitis C

Share to Imidazoles

Share to Pyrrolidines

Share to Valine

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26170396
DOI: 10.1093/infdis/jiv379
PMCID: PMC4690147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.PMID 26170396Read ↗

Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.Semantic proximity Read ↗

Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.Semantic proximity Read ↗

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.Semantic proximity Read ↗

Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes.Semantic proximity Read ↗

Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.Semantic proximity Read ↗

Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir.Semantic proximity Read ↗

Hepatitis C virus genotype 4: A poorly characterized endemic genotype.Semantic proximity Read ↗

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.Semantic proximity Read ↗

Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.Semantic proximity Read ↗

Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.Semantic proximity Read ↗

Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.Semantic proximity Read ↗

Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.